Capromorelin has no FDA-approved human indication; all current use is off-label or sourced through compounding pharmacies. The human clinical record is minimal — one thin trial in actinic keratosis, with remaining evidence confined to animal models. There are no established dosing protocols or documented community use patterns to report, and the evidence base is genuinely thinner than the volume of surrounding interest suggests.

Research Evidence
Evidence shape
Capromorelin's clinical record consists of one registered trial — Phase 1, in Actinic Keratosis — with a single linked publication and no results posted at scale. The remaining mapped research is preclinical: animal and mechanistic work that hasn't progressed to registered human trials. With nothing beyond Phase 1 and only one indication reaching any human-study threshold, the evidence base doesn't support conclusions about efficacy in any indication.
Anecdotal efficacy
Side effects
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Price
No live vendor pricing captured for this peptide yet.
Dosing & Protocol
How Capromorelin is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Anecdotal reports consistently highlight positive effects on appetite stimulation and increased food intake, with 3 out of 3 reports being positive. Specific dosing information is not consistently available in community discussions.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Peptide feedback
0 forum repliesLive community discussion for Capromorelin, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.